Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on >= 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)-MedSci.cn

Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on >= 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)

Escudier, B; Motzer, RJ; Dyer, M; May, JR; Ejzykowicz, F; Kurt, M; Lee, CW; Wang, P; Testa, E; Sharpe, DJ; George, S; Tannir, N

ANNALS OF ONCOLOGY, 2022; 33 (7): S1212